1/87
Looks like no tags are added yet.
Multiple Sclerosis (MS)
Characterized by CNS demyelination and axonal damage, and is thought to be a chronic inflammatory and neurodegenerative disorder
high-dose
- IV/PO Methylprednisolone
- The onset of clinical response is typically within 3-5 days
Exacerbations or relapses of MS can be disabling and are treated with ___-dose glucocorticoids
lesions or plaques
- primarily found in the brain, spinal cord, and optic nerves
Demyelization leads to the formation of the MS ____
- Numbness, tingling
- Walking difficulty
- Vision problems
- Weakness
- Dizziness
- Depression
- Muscle spasms
- Bladder dysfunction
- Bowel dysfunction
- Pain
- Cognitive dysfunction
Typical clinical presentation of MS
≥24 hours
A relapse or clinical attack usually lasts ≥____ hours.
- Optic neuritis: unilateral, painful, blurry vision
- Myelitis: numbness and weakness in torso/extremities
Common relapse symptoms
The first clinical neurologic episode caused by CNS demyelination that lasts ≥ 24 hours and does not yet meet criteria for MS.
What is Clinically Isolated Syndrome (CIS)?
63%
Approximately what percentage of patients with CIS will progress to MS?
Relapsing-remitting multiple sclerosis (RRMS) [85%]
What is the most common form of MS at diagnosis?
Relapses of new or worsening neurologic symptoms followed by periods of recovery (remission)
How is RRMS clinically characterized?
Secondary Progressive Multiple Sclerosis (SPMS)
What occurs after RRMS, in which neurologic disability progressively worsens independent of relapses?
Because clinicians cannot predict exactly when progression begins and must identify it over time
Why is SPMS considered a retrospective diagnosis?
Progressive neurologic disability from disease onset, without relapses
What distinguishes Primary Progressive MS (PPMS) from other MS types?
Ocrelizumab (Ocrevus)
What is the only FDA-approved disease-modifying therapy for PPMS?
1. Visual complaints: unilateral vision loss (optic neuritis) or double vision
2. Spasticity
3. Gait problems, falls
4. Bowel and bladder dysfunction
5. Sexual dysfunction
6. Weakness, ataxia
7. Speech difficulty
8. Psychological changes
9. Cognitive changes
10. Fatigue
Primary symptoms of MS
1. Recurrent UTIs
2. Renal calculi
3. Decubiti and osteomyelitis
4. Osteoporosis
5. Respiratory infections
6. Poor nutrition
Secondary symptoms of MS
TCAs
- anticholinergic side effects, orthostatic hypotension, sedation
Which class of antidepressants should be avoided in most MS patients?
MRI
Gold standard for MS diagnosis
- also identifies lesions for treatment monitoring
Presence of lesions throughout the brain and spinal cord
What is dissemintation in space (DIS)?
Development of new lesions over time
What is dissemintation in time (DIT)?
Temporary worsening or recurrence of symptoms indicative of nerve inflammation from demyelination
- Must last at least 24 hours +/- recovery without fever or infection
What defines acute relapse in MS?
(in order of preference)
1. Methylprednisolone 500 - 1000 mg IV daily x 3-7 days
2. Prednisone 1250 mg PO daily x 3-7 days (heavy tablet burden)
3. Acthar Gel 80-120 units IM/SubQ daily x 7 days
- Directly stimulates the adrenal cortex to synthesize and release steroids
- Highly purified ER preparation of adrenocorticotropic hormone (ACTH)
- Inadequate or intolerable response to corticosteroids
4. Steroid refractory relapse: Plasma exchange daily x 3-7 days
Treatment for acute relapse
plasma exchange daily for 3-7 days
If a patient cannot tolerate or does not respond to steroids for the management of an acute relapse, what is used?
- Glatiramer acetate (Copaxone, Glatopa)
- Interferon beta-1a (Avonex, Rebif)
- Interferon beta-1b (Betaseron)
- PegINF beta-1b (Plegridy)
What are the platform therapies for MS?
- indicated for CIS, RRMS, SPMS
- good safety profile, but only modestly effective
- place in therapy: patient concern for safety/AEs and pregnancy
Glatiramer acetate (Copaxone, Glatopa) 20 mg SQ daily or 40 mg TIW
Platform therapy for MS that blocks T-cell-mediated myelin damage by acting as a decoy and mimicking the myelin sheath
- approved for CIS, RRMS, SPMS
- place in therapy: patient concern for safety/AEs and pregnancy
1. Interferon beta-1a
- Avonex 30 mcg IM weekly
- Rebif 22 mcg SQ TIW
2. Interferon beta-1b (Betaseron) 0.25 mg SQ QOD
3. PegINF beta-1b (Plegridy) 125 mcg SQ/IM every 2 weeks
Platform therapies for MS that inhibit T-cell activation and migration to the CNS
- approved for CIS, RRMS, SPMS
- place in therapy: patient concern for safety/AEs and pregnancy
Does not require laboratory monitoring
What is a major advantage of Glatiramer acetate (Copaxone, Glatopa)?
Lipoatrophy, vasodilation, injection site skin hardening
- counsel patients to rotate injection sites and to apply a cold compress to the injection site and take NSAIDs prior to administering
SEs of Glatiramer acetate (Copaxone, Glatopa)
- flu-like symptoms: HA, chills, myalgia, fever (usually transient; can counsel patient to take NSAID or Tylenol to reduce pain)
- worsening depression
- worsening HF
- increased LFTs
- increased seizure risk
- anemia, leukopenia, thrombocytopenia
SEs of the interferons
- Interferon beta-1a (Avonex, Rebif)
- Interferon beta-1b (Betaseron)
- PegINF beta-1b (Plegridy)
heart failure
Avoid interferons in patients with ____
Indicated for CIS, RRMS, SPM
- after Glatiramer/IFN due to injection fatigue
Place in therapy for Teriflunomide (Aubagio) 7 or 14 mg PO daily
A pyrimidine synthesis inhibitor that decreases CNS B and T lymphocytes
MOA of Teriflunomide (Aubagio)
1. Teratogenicity: if d/c, administer Cholestyramine for 11 days
2. Hepatotoxicity: monitor LFTs monthly
BBW for Teriflunomide (Aubagio)
men planning to father children
- if d/c, administer Cholestyramine for 11 days
Avoid Teriflunomide (Aubagio) in:
Hair thinning
Hepatotoxicity (monitor LFTs monthly)
SEs of Teriflunomide (Aubagio)
CIS, RRMS, SPMS oral therapy
- Fingolimod: highly active disease
Place in therapy for the Sphingosine 1-Phosphate (S1P) Receptor Modulators
Sequesters lymphocytes within lymph nodes and prevents migration into the CNS
MOA of the Sphingosine 1-Phosphate (S1P) Receptor Modulators
1. Fingolimod (Gilenya)
2. Ozanimod (Zeposia)
3. Ponesimod (Ponvory)
4. Siponimod (Mayzent)
all administered PO once daily
List the Sphingosine 1-Phosphate (S1P) Receptor Modulators
- Bradycardia
- QT prolongation
- Macular edema (baseline ophthalmologic exam)
AEs of the Sphingosine 1-Phosphate (S1P) Receptor Modulators
Ophthalmologic
Which baseline exam is required prior to starting a Sphingosine 1-Phosphate (S1P) Receptor Modulator?
1. MI in the past 6 months
2. Unstable angina
3. Class III/IV HF
4. Uncontrolled HTN
Contraindications for the Sphingosine 1-Phosphate (S1P) Receptor Modulators
EKG
____ monitoring for the first dose of Fingolimod (Gilenya) is recommended for ≥6 hours.
CYP2C9
Which genotype testing is needed for Siponimod (Mayzent)?
1. Class Ia and III antiarrhythmics
- Ia: Quinidine, Procainamide, Disopyramide
- III: Amiodarone, Sotalol, Dofetilide, Ibutilide
2. Agents that prolong QT: Macrolides, FQs, Ondansetron, Citalopram, Ziprasidone
3. Agents that slow HR: beta-blockers, non-DHP CCBs, Digoxin
4. Immunosuppressants
5. Live vaccines: MMR, Varicella, Flumist
6. Ketoconazole
Fingolimod (Gilenya) drug interactions
CIS, RRMS, SPMS oral therapy
- Dimethyl used in highly active disease
- slower dose titration schedule over two weeks
Place in therapy for fumarates
1. Dimethyl fumarate (Tecfidera)
2. Diroximel fumarate (Vumerity)
3. Monomethyl fumarate (Bafiertam)
- all PO twice daily with a slow titration schedule over 2 weeks
- administer with high-fat, high-protein, low-starch food
List the fumarates
1. flushing
2. GI symptoms: nausea, diarrhea, abdominal pain
SEs of the fumarates
Lower infection risk compared to high-efficacy therapies
Advantages of the fumarates
1. Administer with high-fat, high-protein, low-starch food
2. Take a non-enteric coated aspirin (≤325 mg) 30 min prior to decrease flushing
Administration counseling points for the fumarates
Monomethyl fumarate (Bafiertam)
Which fumarate has improved GI tolerability?
RRMS, SPMS in patients with highly active disease or those who have issues with nonadherence
Place in therapy for Cladribine (Mavenclad)
- Given as two yearly courses, with each year consisting of 2 treatment courses of 4-5 consecutive days
Impairs DNA synthesis, depleting B and T lymphocytes
MOA of Cladribine (Mavenclad)
men planning to father a child
Avoid Cladribine (Mavenclad) in:
1. URTI
2. Lymphopenia
3. Herpes zoster
AEs of Cladribine (Mavenclad)
Herpes zoster
Patients must be screened for ____ prior to starting Cladribine (Mavenclad)
Malignancy
Teratogenicity
BBW for Cladribine (Mavenclad)
Hepatitis, TB, HIV
Monitor for which infections while on Cladribine (Mavenclad)?
CIS, RRMS, SPMS for highly active disease
- minimizes infusion reactions
Place in therapy for Natalizumab (Tysabri) IV monthly
- only available through TOUCH REMS Program
Monoclonal antibody that binds alpha4 integrin to block T-cell migration into the CNS
MOA of Natalizumab (Tysabri)
Progressive multifocal leukoencephalopathy (PML) risk
- increased in patients with JCV (+) antibodies and use >2 years
- TOUCH REMS Program
- JCV serology every 6 months
BBW for Natalizumab (Tysabri)
HA, UTI, depression, diarrhea
SEs of Natalizumab (Tysabri)
every 6 months
How often should JCV antibody testing be performed while on Natalizumab (Tysabri)?
1. Ocrelizumab (Ocrevus) IV infusion every 6 months
2. Ofatumumab (Kesimpta) SQ monthly
3. Ublituximab (Briumvi) IV infusion every 6 months
Humanized monoclonal antibodies that bind to CD20, suppressing and depleting circulating B-cells.
CIS, RRMS, SPMS, [PPMS → Ocrelizumab ONLY]
- Monoclonal Abs are not first-line for MS
- Less PML risk and less frequent infusions
Place in therapy for the anti-CD20 monoclonal antibodies
Infusion reactions, URTI
SEs of the anti-CD20 monoclonal antibodies
1 hour
How long should patients be observed after Ocrelizumab (Ocrevus) infusion?
RRMS, SPMS in patients with an inadequate response to ≥2 DMTS or with highly active disease
- REMS Program
Place in therapy for Alemtuzumab (Lemtrada)
- Year 1: IV infusion x 5 days
- Year 2: IV infusion x 3 days
Monoclonal antibody that binds CD52 surface antigen on B and T cells, NK cells, and macrophages to prevent the downstream inflammatory cascade
MOA of Alemtuzumab (Lemtrada)
Infusion reactions, autoimmune diseases, malignancy
BBW of Alemtuzumab (Lemtrada)
1. Infections: HSV, HPV, TB
2. Malignancy: thyroid, melanoma
3. Autoimmune diseases: thyroid, immune thrombocytopenia
SEs of Alemtuzumab (Lemtrada)
Monthly
How often should labs be done when receiving Alemtuzumab (Lemtrada)?
Acyclovir
What is prescribed with Alemtuzumab (Lemtrada) for HSV prophylaxis?
Refractory RRMS and SPMS
- typically not prescribed due to AEs and there being better therapies available; most often utilized as an oncologic agent
Place in therapy for Mitoxantrone (Novantrone) IV infusion every 3 months (lifetime cumulative dose: 140 mg/m2)
Inhibits B and T cell and macrophage proliferation and impairs antigen presentation
MOA of Mitoxantrone (Novantrone)
Cardiotoxicity
BBW of Mitoxantrone (Novantrone)
n/v/d, leukopenia
SEs of Mitoxantrone (Novantrone)
PML is caused by reactivation of latent John Cunningham virus (JCV) in immunocompromised patients, particularly those on MS therapies that reduce immune surveillance in the CNS
What causes Progressive Multifocal Leukoencephalopathy (PML), who is at risk, and why does it occur in MS patients on certain DMTs?
Immediately discontinue the disease-modifying therapy and consider plasmapheresis to remove the offending drug.
What is the immediate management when PML is suspected in an MS patient?
Skin assessment
What baseline assessment is recommended before starting interferons?
TB, pregnancy
What baseline screenings are required before starting teriflunomide?
monthly
How often are liver function tests monitored with teriflunomide?
VZV IgG, ECG, and ophthalmologic exam
What baseline tests are required before initiating S1P receptor modulators?
VZV IgG, HIV, hepatitis B, hepatitis C, TB, and pregnancy
What baseline tests are required before starting cladribine?
JCV antibodies, HIV testing, and brain MRI
What baseline tests are required before initiating natalizumab?
VZV IgG, HIV, hepatitis B, hepatitis C, and TB screening
What baseline infection screening is required before alemtuzumab therapy?
Monthly CBC monitoring
What ongoing laboratory monitoring is required with alemtuzumab?
VZV IgG, HIV, hepatitis B, hepatitis C, and TB screening
What baseline screening is required before starting anti-CD20 monoclonal antibodies?
As frequently as monthly (Lemtrada) or every 6 months for 1-2 years.
How often may DMT monitoring occur after therapy initiation?